These observations can explain the lack of efficacy of anti-VEGF agents since the positive effect of blood supply reduction is counteracted by indirect pro-angiogenic and pro-inflammatory effect, thus suggesting the possibility to add anti-inflammatory agents in the therapy of pancreatic cancer. The gene discussed is VEGFA; the disease is familial pancreatic carcinoma.